Company Directory - NeoGenomics, Inc.
Company Details - NeoGenomics, Inc.
NeoGenomics, Inc.
WebsiteFort Myers, United States
NeoGenomics, Inc. is a leading provider of cancer-focused genetic testing and information services. The company offers innovative diagnostic testing services primarily for oncologists and pathologists, enhancing patient care through advanced genomic testing.
CCI Score
CCI Score: NeoGenomics, Inc.
20.21
-0.09%
Latest Event
NeoGenomics Political Spending Profile Released by OpenSecrets
The OpenSecrets profile on NeoGenomics revealed that for the 2024 cycle, the company made a minimal campaign contribution of $57 while spending $60,000 on lobbying. The data, drawn from public disclosures by the Senate Office of Public Records and other agencies, highlights the company's engagement in political spending.
Take Action
So what can you do? Support NeoGenomics by shopping, spreading the word, or offering your support.
- Shop Alternatives
SEE ALL - Use Your Voice
OTHER TOOLS - Investigate
- Share the Score
SUPPORT CCI
SABOTEUR
NeoGenomics, Inc. is currently rated as a Saboteur.
Latest Events
- FEB192025
The OpenSecrets profile on NeoGenomics revealed that for the 2024 cycle, the company made a minimal campaign contribution of $57 while spending $60,000 on lobbying. The data, drawn from public disclosures by the Senate Office of Public Records and other agencies, highlights the company's engagement in political spending.
-10
Political Contributions and Lobbying Efforts
April 30
The reported political spending, though relatively modest, indicates NeoGenomics' participation in lobbying efforts. From an anti-fascist perspective, any corporate attempt to influence political processes—even through small expenditures—raises concerns about potential indirect support of authoritarian outcomes.
- SEP232024
On September 23, 2024, the District Court for the Middle District of North Carolina issued a permanent injunction against NeoGenomics’ accused RaDaR assay in a patent infringement dispute initiated by Natera, Inc. The ruling calls into question NeoGenomics’ business practices regarding ethical competition and transparency.
-50
Business Practices and Ethical Responsibility
April 30
The permanent injunction following a patent infringement case suggests that NeoGenomics engaged in questionable business practices by allegedly pursuing aggressive, potentially unethical strategies that undermine fair competitive practices. Such actions can be seen as undermining the ethical responsibility expected in corporate conduct, reflecting poorly on the company from an accountability and transparency perspective.
Court Orders Permanent Injunction Against NeoGenomics' Accused RaDaR Assay, as Case Enters New Phase
- MAR202024
On March 20, 2024, NeoGenomics, Inc. released its inaugural ESG report, detailing significant progress in environmental stewardship, workforce diversity, and corporate governance. The report highlights initiatives such as improved recycling practices at laboratory sites, robust diversity and inclusion metrics, and an expanded board of directors, marking a commitment to ethical business practices.
+70
Business Practices and Ethical Responsibility
April 30
The ESG report underscores NeoGenomics' commitment to ethical business practices by advancing sustainability measures, transparent governance, and strong diversity and inclusion initiatives. These efforts promote responsible corporate behavior that resists authoritarian tendencies.
NeoGenomics Releases Inaugural Environmental, Social, and Governance (ESG) Report
+60
Labor Relations and Human Rights Practices
April 30
The report demonstrates a strong commitment to labor relations and human rights through significant improvements in workforce diversity and an inclusive environment. Metrics such as high female representation and ethnic diversity indicate positive steps toward countering systemic inequalities.
NeoGenomics Releases Inaugural Environmental, Social, and Governance (ESG) Report
- MAR202024
NeoGenomics, Inc. released its first Environmental, Social, and Governance (ESG) report, highlighting its commitment to diversity, equity, inclusion, environmental stewardship, and improved employee engagement, with strong metrics demonstrating progress in supporting marginalized groups and sustainable practices.
+80
Labor Relations and Human Rights Practices
April 30
The ESG report underscores NeoGenomics' commitment to robust diversity and inclusive labor practices by reporting strong metrics, such as 59.9% female global workforce and 53.5% ethnically diverse US workforce, as well as efforts to engage employees and reduce turnover. This initiative aligns with progressive, anti-fascist values by promoting worker rights and inclusion, effectively resisting exclusionary and authoritarian business practices.
NeoGenomics Releases Inaugural Environmental, Social, and Governance (ESG) Report
- MAR202024
NeoGenomics reported the release of its 2023 ESG report, detailing initiatives in environmental stewardship, workforce diversity, and inclusive practices, including recycling efforts and improvements in employee engagement metrics. The report underscores the company’s commitment to building a sustainable, ethical, and diverse workplace.
+70
Business Practices and Ethical Responsibility
April 30
The ESG report demonstrates strong commitment to ethical business practices, including significant efforts in workplace diversity, sustainability measures like recycling initiatives, and overall corporate responsibility. These measures align with anti-fascist values by promoting inclusivity and environmental stewardship.
NeoGenomics Releases Inaugural Environmental, Social, and Governance (ESG) Report
- DEC312023
NeoGenomics Laboratories spent $20,000 on lobbying activities in 2023, as reported by OpenSecrets, indicating its engagement in influencing public policy.
-15
Political Contributions and Lobbying Efforts
April 30
The reported $20,000 lobbying expenditure by NeoGenomics in 2023 reflects the company’s active involvement in influencing policy decisions. From an anti-fascist perspective, even modest lobbying efforts contribute to corporate influence in the political arena, raising concerns about potential support for authoritarian policies.
Alternatives
Corporation
-37.82
Somerset, United States
1.17
Cranbury, United States
-14.96
Sunnyvale, United States
-32.62
Seattle, United States
-37.70
Menlo Park, United States
-49.21
Belgium (Ghent), Belgium
78.10
Raleigh, USA
55.85
Moradabad, India
0.00
Basel, Switzerland
-19.51
Corporate Financials
- Revenue
- 2024
- $217.50M
- Total Assets
- 2024
- $568.00M
- Operating Income
- 2024
- $30.00M
- Total Equity
- 2024
- $216.00M
Employees: 1,200
Industries
- 621511
- Medical Laboratories
- 621512
- Diagnostic Imaging Centers
- 541711
- Research and Development in Biotechnology